Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Global Product Strat. | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 7,390 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 7,390 · Balance 7,390 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 01:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,390 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000030 · form4.xml · derivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,390 Underlying: Common Stock · 7,390 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · derivative · entry 9 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,087 Underlying: Common Stock · 3,043 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,802 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · derivative · entry 8 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,802 Underlying: Common Stock · 1,802 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,044 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · derivative · entry 7 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,044 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 775 | $201.18 | $155,914.50 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 6 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,011 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,043 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 5 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 458 | $201.18 | $92,140.44 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,743 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,802 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 805 | $201.18 | $161,949.90 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,399 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000019 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Total adjusted to reflect transfer of shares to the reporting person's former spouse pursuant to a Domestic Relations Order. Read SEC document |
| July 08, 2025 Filed Jul 16, 2025 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 2,223 | $135.00 | $300,105.00 |
DisclosureSEC source: 0001127602-25-019295 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,330 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,515 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004452 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,515 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 445 | $142.54 | $63,430.30 |
DisclosureSEC source: 0001127602-25-004452 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,553 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004452 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Total adjusted to reflect transfer of shares to the reporting person's former spouse pursuant to a Domestic Relations Order. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,801 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · derivative · entry 6 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,604 Underlying: Common Stock · 1,801 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · derivative · entry 5 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,044 Underlying: Common Stock · 2,043 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · nonDerivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 565 | $141.35 | $79,862.75 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · nonDerivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,059 Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 600 | $141.35 | $84,810.00 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,624 Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 02:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004243 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Total adjusted to reflect transfer of shares to the reporting person's former spouse pursuant to a Domestic Relations Order. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:49 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 9,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003959 · form4.xml · derivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,130 Underlying: Common Stock · 9,130 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 807 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · derivative · entry 7 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 807 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 647 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · derivative · entry 6 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 647 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 1,370 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · derivative · entry 5 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,370 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 313 | $219.08 | $68,572.04 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,701 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 639 | $219.08 | $139,992.12 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,367 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,515 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004794 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,515 Underlying: Common Stock · 1,515 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 445 | $240.98 | $107,236.10 |
DisclosureSEC source: 0001127602-24-004794 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,636 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004794 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004308 · form4.xml · derivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,087 Underlying: Common Stock · 2,043 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 621 | $240.30 | $149,226.30 |
DisclosureSEC source: 0001127602-24-004308 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,566 Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004308 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004308 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,405 Underlying: Common Stock · 5,405 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:31 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 1,370 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002807 · form4.xml · derivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,370 Underlying: Common Stock · 1,370 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 504 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020238 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 504 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on July 1, 2020, and vested in three equal installments on each anniversary of the grant date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 244 | $284.85 | $69,503.40 |
DisclosureSEC source: 0001127602-23-020238 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,144 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 504 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020238 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 681 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006513 · form4.xml · derivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 681 shares Expires 2024-02-18 F2 · kind: This number represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 767 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006513 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,135 Underlying: Common Stock · 767 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 371 | $278.38 | $103,278.98 |
DisclosureSEC source: 0001127602-23-006513 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,117 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 767 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006513 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 553 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · derivative · entry 8 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 553 shares Expires 2023-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 453 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · derivative · entry 7 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553 Underlying: Common Stock · 453 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,515 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · derivative · entry 6 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,030 Underlying: Common Stock · 1,515 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 642 | $286.30 | $183,804.60 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 5 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,488 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 220 | $286.30 | $62,986.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,130 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 462 | $286.30 | $132,270.60 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,897 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.